-
Dow Biotech signed a license agreement with Lonza to develop multispecific biotherapeutics using XS Pichia
Time of Update: 2021-12-28
62em; font-family:"Arial"; color:black; margin:0in; } </> DOER Bio is currently applying its unique MultipleBody ® and SMART-VHHBody technology platforms to develop multispecific antibody therapeutics This license agreement will authorize Doer Biologics to use Lonza’s XS ® Pichia expression system to produce such important drugs Basel, Switzerland and Hangzhou, China, December 14, 2021/PRNewswire/ - Zhejiang Doer Biotechnology Co.
-
Merck announces the creation of Athinia, a semiconductor manufacturing data platform
Time of Update: 2021-12-28
The Athinia platform will use artificial intelligence and big data analysis to help address a series of key challenges facing the global semiconductor industry, including semiconductor chip shortages, product quality, time to market, and supply chain transparency .
-
Bena Gene completes 25 million yuan in PreA round of financing
Time of Update: 2021-12-28
The introduction of the Ruijiang Kangsheng Fund this time, combined with the strong financial support of the fund, professional operation and management capabilities and the advantages of Kangsheng Global in the field of medical special inspections, the company will accelerate the development process of products in the field of clinical medical testing.
-
Zhong Nanshan: China's new crown drugs are valuable for promotion worldwide
Time of Update: 2021-12-28
Zhong Nanshan, an academician of the Chinese Academy of Engineering, presided over the Phase II clinical study of the drug in China, and took the lead in demonstrating and promoting the emergency treatment of the drug in China, further verifying the safety and effectiveness of the drug in Chinese patients .
-
WuXi AppTec's announcement on recent stock market fluctuations
Time of Update: 2021-12-27
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
62em; font-family:"Arial"; color:black; margin:0in; } </>Shanghai, December 16, 2021/PRNewswire/ - The company is currently operating normally, and is confident of future business growth, continued empowerment of global customers, and benefits to patients around the world .
-
The total number of approved indications reached 8, and Hengrui Medicine Carrelizumab added two new indications
Time of Update: 2021-12-27
The results of the study showed that, as assessed by the independent review committee, the median progression-free survival (mPFS) of patients in the carrelizumab combined chemotherapy group reached 8.
-
Thermo Fisher releases NGS test kit for myeloid hematological tumors
Time of Update: 2021-12-27
Oncomine Myeloid Assay GX v2 provides a comprehensive combination that requires minimal manual operation time to analyze key biomarkers of major myeloid diseases .
Thermo Fisher says that it is optimized to detect a variety of variants, including targets that are difficult to sequence, such as FLT3-ITD, CALR, and CEBPA .
-
The China Women's Development Foundation and Thermo Fisher officially launch the growth plan for female scientists
Time of Update: 2021-12-27
December 15, 2021, Shanghai-The Women Scientists Growth Plan jointly created by the China Women's Development Foundation (hereinafter referred to as the Women's Foundation) and Thermo Fisher Scientifi
-
Twist Bioscience launches circulating tumor DNA reference standard, suitable for the development of liquid biopsy analysis
Time of Update: 2021-12-27
South San Francisco, California, USA--(Business Wire)--December 7, 2021--Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers A successful company, the company announced the launch of the Twist cfDNA pan-cancer reference standard, a high-quality standardized control that can be used for the development and continuous monitoring of liquid biopsy tests to detect cancer through blood samples .
-
KingScript won the "Annual New Crown Management Plan" award from "Singapore Business Review"
Time of Update: 2021-12-27
GenScript has given strong support to global new coronavirus prevention and control, including the production of genes, proteins and peptides for the global development of new coronavirus vaccines, and launched the first FDA EUA (Emergency Use Authorization) neutralizing antibody test kit—— cPass?
-
BeiGene Announces Completion of an Initial Public Offering of 22.2 billion RMB (3.5 billion USD) of shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange
Time of Update: 2021-12-27
62em; font-family:"Arial"; color:black; margin:0in; } </>Cambridge, MA, USA and Beijing, China, December 15, 2021/PRNewswire/ - BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235) is a company based on science Of global biotechnology companies, focusing on the development of innovative and affordable drugs, aiming to improve the effectiveness of treatment and increase the availability of drugs for patients around the world .
-
The LEC Laboratory Efficiency Conference ended successfully, and the "Baige Win-Win" program officially set sail!
Time of Update: 2021-12-26
iLabService explains Science and technology will start from the actual needs of scientific researchers, solve the pain points faced in real scenes, provide integrated solutions for the laboratory, and help the laboratory's long-term operation and development .
-
Meeting the Wave of Winter Olympics Information Technology Escorts the 2022 Beijing Winter Olympics
Time of Update: 2021-12-26
In order to ensure the smooth progress of the Winter Olympics, Inspur Information and Chongli Hospital have joined hands to adopt a modular data center to provide green and efficient information support services for medical emergency services for the Winter Olympics .
-
The gospel for lung cancer patients in China-China's innovative drug Aifusha (R) enters the national medical insurance reimbursement catalog
Time of Update: 2021-12-26
In March of this year, vometinib was approved in China for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients who have experienced disease progression during or after treatment with EGFR-TKI and have EGFR T790M mutation-positive .
-
Significant progress has been made in anti-aging research in Chinese medicine
Time of Update: 2021-12-26
The argument was unanimously agreed that the preliminary research of the project established the theory of essence, energy and spirit based on the theory of qi and collaterals for the first time, forming a new idea for anti-aging research; the patented traditional Chinese medicine Bazi Bushen Capsule developed by Yiling Pharmaceutical Co.
-
China's innovative drug Nerlik® is launched to break the drug-resistant dilemma of CML-resistant patients
Time of Update: 2021-12-26
Chen Kaixian, academician of the Chinese Academy of Sciences and deputy chief technical engineer of major new drug creation, said in an interview with reporters on the 19th: "Nelic® is China's third-generation BCR-ABL inhibitor, which effectively solves China's drug-resistant chronic myelogenous leukemia.
-
Venus Vitae, a new generation of Venus Vitae bulb expandable valve, successfully completed the world's first two clinical applications
Time of Update: 2021-12-25
HK) announced its independence The new generation of aortic valve replacement (TAVR) system Venus Vitae developed by the company has successfully completed two clinical trials in humans (First-in-Man, FIM) in Argentina on December 16 .
-
Inauguration of BeiGene Bio-Island Innovation Center
Time of Update: 2021-12-25
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prne
-
Hengrui's innovative drug apatinib for the treatment of thyroid cancer is honored in "JAMA Oncology"
Time of Update: 2021-12-25
777) published online a phase III clinical study of apatinib (REALITY)- -A multi-center, randomized, double-blind, placebo-controlled clinical study of apatinib mesylate tablets in the treatment of locally advanced/metastatic radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) patients .
-
The opening of the China Rare Disease Conference in 2021 invites everyone to discuss the prevention and protection of rare diseases
Time of Update: 2021-12-24
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prne
